Considering the low frequency of FGFR2 amplification and its poor concordance with FGFR2 mRNA expression [105], IHC could be a faster and more efficient screening tool to stratify patients with GC who are likely to benefit from FGFR2-targeted therapy. The gene discussed is FGFR2; the disease is gastric cancer.